The Impact of Recent Generic Drug Price Policies on Pharmaceutical Innovation: A Theoretical Rationale and Proposal of a Method Supporting Innovation in Areas of Unmet Medical Need

New discoveries are a critical priority for the pharmaceutical industry. However, the use of fixed incremental cost-effectiveness (ICER) thresholds for health technology assessment (HTA) may compromise incentives to innovate and affect future treatment options. This paper highlights the impact of ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Dionne, Pierre-Alexandre, Ali, Farzad, Grobler, Mendel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2016
Materias:
Methodology and Healthcare Policy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341815/
https://www.ncbi.nlm.nih.gov/pubmed/34430665
http://dx.doi.org/10.36469/9838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8341815/
https://www.ncbi.nlm.nih.gov/pubmed/34430665
http://dx.doi.org/10.36469/9838

Ejemplares similares